Physician profile
Andrew J Epstein
NPI 1801877584
$3,198.84
in general payments reported to CMS, 2019-2025
21 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $333 · 2021: $564 · 2022: $158 · 2023: $515 · 2024: $399 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $809.30 | 2019-2025 | Clareon, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $725.50 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $584.79 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $180.72 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.10 | 2019-2021 | |
| Allergan, INC. | $117.28 | 2020-2022 | |
| Medtronic, INC. | $115.93 | 2025 | Sphere-9, Affera Mapping System |
| Abbvie INC. | $100.66 | 2023-2025 | |
| Kala Pharmaceuticals, INC. | $97.31 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $77.70 | 2024-2025 | |
| Janssen Biotech, INC. | $57.33 | 2023-2025 | Tremfya, Stelara |
| Oyster Point Pharma, INC. | $29.59 | 2024 | Ryzumvi, Tyrvaya |
| Biotissue Holdings INC. | $27.78 | 2022 | |
| Dompe US, INC. | $26.64 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $22.90 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.05 | 2023 | Tepezza |
| Akorn, INC. | $13.96 | 2019 | |
| Eyepoint US, INC. | $13.43 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.31 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.06 | 2021 | |
| Akorn Operating Company LLC | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.